A Study to Characterize Profile of Participant With Psoriatic Arthritis Depending on Whether Their Disease is Managed by a Dermatologist or by a Rheumatologist, and Starting Ustekinumab

Sponsor
Janssen Cilag S.A.S.
Study ID
NCT03336281
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Ustekinumab — DRUG
    All participants will receive ustekinumab at study entry. Ustekinumab will not be provided by the sponsor. The treatment decision must have been taken by the investigator prior to, and independently of the participant's inclusion into the study following the standard clinical practice. Only data available from a participant's source medical records will be collected.

Study Details

The primary purpose of this study is to describe the Psoriatic Arthritis (PsA) participant profiles depending on whether their disease is managed by a dermatologist or by a rheumatologist in routine practice.

Key Dates

Start date
Apr 25, 2017
Status verified
Jan 2025
Primary completion
Apr 7, 2020
Completion
Apr 7, 2020

Study Design

Enrollment
221 participants (actual)

Arms

  • Arm: Participants with Psoriatic Arthritis: Dermatologist Cohort
    Participants who will receive ustekinumab (as a first or second line of biologic disease modifying anti-rheumatic drug \[bDMARD\] therapy) along with other co-medications as per clinical dematologist's discretion will be observed in this study. Ustekinumab will not be provided by the sponsor. The treatment by ustekinumab must have been decided by the physician prior to the decision to include the participant in the study. Only data available from a participant's source medical records will be collected. Additionally investigators will be asked to obtain (or record where available) Patient-Reported Outcome (PRO) data from participants participating in this study.
  • Arm: Participants with Psoriatic Arthritis: Rheumatologist Cohort
    Participants who will receive ustekinumab (as a first or second line of bDMARD therapy) along with other co-medications as per clinical rheumatologist's discretion will be observed in this study. Ustekinumab will not be provided by the sponsor. The treatment by ustekinumab must have been decided by the physician prior to the decision to include the participant in the study. Only data available from a participant's source medical records will be collected. Additionally investigators will be asked to obtain (or record where available) PRO data from participants participating in this study.

Primary Outcome Measure

Number of Participants With Swelling of Joints at Baseline [ Time Frame: Baseline (Week 0) ]

Related Studies